Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Walgreens profit beats estimates on PBM partnerships

Published 01/05/2017, 07:45 AM
Updated 01/05/2017, 07:45 AM
© Reuters. The Walgreens store in Times Square seen in New York

(Reuters) - Walgreens Boots Alliance Inc (O:WBA) reported a better-than-expected quarterly profit as recent partnerships with pharmacy benefit managers (PBMs) and insurance companies helped boost sales of prescription drugs as well as non-drug items.

The largest U.S. drugstore chain also raised the lower end of its adjusted profit forecast for the year ending August 2017.

Walgreens, which is awaiting regulatory approval for its $9.5 billion takeover of smaller rival Rite Aid Corp (N:RAD), said it expects to close the deal early this year.

It had previously extended the merger agreement till Jan. 27.

Walgreens entered partnerships last year with PBMs such as Express Scripts Holding Co (O:ESRX) and OptumRx and insurer UnitedHealthcare (N:UNH) which helped boost sales in the first quarter.

Net income attributable to Walgreens fell to $1.05 billion, or 97 cents per share, in the first quarter ended Nov. 30, from $1.11 billion, or $1.01 per share, a year earlier.

Excluding items, the company earned $1.10 per share, beating the average analysts' estimate of $1.09, according to Thomson Reuters I/B/E/S.

Sales fell to $28.50 billion from $29.03 billion, falling for the first time in four years and missing the analyst estimate of $29.23 billion.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.